From:  Significance of next-generation sequencing in the era of targeted therapy for biliary tract cancer: an analysis at a single institution

 Details of next-generation sequencing (NGS).

Variablesn (%)
NGS platform used
    FoundationOne® CDx (F1)59 (90%)
    FoundationOne® Liquid (F1L)3 (5%)
    Guardant360® (G)3 (5%)
Sample type for F1 (n = 59)
    Primary resection specimen32 (54%)
    Primary tumor biopsy13 (22%)
    Metastatic resection specimen13 (22%)
    Metastatic tumor biopsy1 (2%)